Addictions Therapeutics Market 2023-2027: 5-Year (2017-2021) Historic Industry Size & Analysis of 15 Vendors and 7 Countries

NEW YORK, Nov. 23, 2022 /PRNewswire/ — The addictions therapeutics market size is estimated to increase by USD 9.86 billion from 2022 to 2027, with an accelerated CAGR of 7.65%, according to the recent market study by Technavio. This report also offers a 5-year historical (2017-2021) data projection of market size, segmentation, and region.

Discover some insights on market size before buying a full report, request a free sample report.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak. The Bargaining Power of Buyers & Suppliers and the Threat of New Entrants, Rivalry, and Substitutes have also been analyzed and rated between LOW-MODERATE to provide a holistic view of market favorability.

Find Technavio’s Exclusive Analysis of Price Sensitivity, Adoption Lifecycle, Customer Purchase Basket, Adoption Rates, and Purchase Criteria

  • One of the core components of the customer landscape is price sensitivity, an analysis of which will help companies refine marketing strategies to gain a competitive advantage. 
  • Another key aspect is price sensitivity drivers (purchases are undifferentiated, purchase is a key cost to buyers, and quality is not important), which range between LOW and HIGH.
  • Furthermore, market adoption rates for all regions have been covered.

The addictions therapeutics market report also offers information on the criticality of inputs, R&D, CAPEX, technology, and products of 15 vendors listed Below –

  • Amneal Pharmaceuticals Inc.
  • Aphios Corp.
  • Braeburn Inc.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals Plc
  • Indivior Plc
  • Johnson and Johnson
  • Kaleo Inc.
  • Mallinckrodt Plc
  • Orexo AB
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Purdue Pharma LP
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Titan Pharmaceuticals Inc.
  • Viatris Inc.

Download a sample report

Chart & Data Table on 5-Year Historic (2017-2021) Market Size, Comparative Analysis of Segments, and Y-O-Y Growth of Addictions Therapeutics Market

  • The market is segmented by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) and Type (Alcohol Addiction Therapeutics, Tobacco Addiction Therapeutics, and Drug Addiction Therapeutics).
  • By Distribution Channel, the hospital pharmacy segment was the market’s largest segment in 2022.
  • The growth of this segment is primarily attributed to a wide range of facilities and advanced infrastructure to cater to the different needs of patients.
  • Hospital groups or multi-specialty or super-specialty hospitals play a key role in terms of sales due to the availability of extensive inpatient and outpatient services, which help them generate high revenue.
  • Hospital pharmacies are witnessing an increasing demand for addiction therapeutics owing to high discounts, improving reimbursement, and the growing number of drug addicts. These factors will positively impact the growth of the hospital pharmacy segment of the global addiction therapeutics market during the forecast period.

To procure the data – Buy report!

High Consumption of Alcohol, Tobacco, and Opioid Products is Notably Driving the Addictions Therapeutics Market Growth

Despite increasing awareness and stringent regulations, the market has witnessed an increase in the consumption of alcohol, opioids, and tobacco products. Opioids are a type of narcotic pain medication that is available as a therapy for the treatment of moderate-to-severe pain in many developed countries. However, the misuse and abuse of opioids lead to opioid tolerance and addiction. This results in substance use disorder, also known as substance dependency. The prevalence of substance use disorders has increased globally owing to the high consumption of alcohol, tobacco, and opioid products. Hence, the high consumption of these substances increases the prevalence of addiction globally, thereby driving market growth.

Chart & Data Table on Historical Market Size (2017-2021, Historic Industry Size & Analysis of 15 Vendors and 7 Countries

The market is segmented by region (North America, Europe, Asia, and the Rest of World). An analysis of key leading countries has been included.

  • North America, which holds the major share of the market, is estimated to contribute 45% to the growth of the global market during the forecast period. Growth will be driven by the increasing consumption of alcohol, tobacco, and opioids in the US and Canada, which is the leading cause of addiction in the US. The prevalence is high among adults with mental health issues, disabilities, and substance use disorders. 
  • In 2020, the COVID-19 pandemic negatively impacted most North American countries, which resulted in the temporary closure of various industries, including those manufacturing addiction therapeutics. The shutdowns adversely impacted their production and distribution activities. Also, as online channels were active even during the pandemic, there was an increased demand for addiction therapeutics. However, in 2021, the demand for addiction therapeutics rebounded from offline retail stores, as regional activities resumed due to the COVID-19 vaccination drives and the subsequent lifting of lockdown restrictions.

For Insights on the market dynamics & segmentations, VIEW A PDF SAMPLE!

Related Reports –

Alzheimer’s Disease Therapeutics Market by Drug Class and Geography – Forecast and Analysis 2022-2026 – size is estimated to increase by USD 3.99 billion from 2021 to 2026, with an accelerated CAGR of 8.76%, according to the recent market study by Technavio.. Furthermore, this report extensively covers market segmentations by drug class (cholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, and other drug class) and geography (North America, Europe, Asia, and Rest of World (ROW)).  To get more exclusive research insights: VIEW SUMMARY OF THE REPORT

Gastrointestinal Stromal Tumors Therapeutics Market by Route of Administration and Geography – Forecast and Analysis 2022-2026 – size is estimated to increase by USD 1.08 billion from 2021 to 2026, with an accelerated CAGR of 5.97%, according to the recent market study by Technavio.  The growing geriatric population is one of the key factors driving the market growth. To get more exclusive research insights: VIEW SUMMARY OF THE REPORT

Register for a free trial today and gain instant access to 17,000+ market research reports. 
Technavio’s SUBSCRIPTION platform

What are the key data covered in this addictions therapeutics market report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the addiction therapeutics market between 2023 and 2027
  • Precise estimation of the size of the addiction therapeutics market size and its contribution to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the addiction therapeutics market industry across APAC, North America, Europe, Middle East and Africa, and South America
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of addiction therapeutics market vendors

Addiction Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2022

Historic Period

2017 -2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 7.65%

Market growth 2023-2027

USD 9.86 billion

Market structure

Fragmented

YoY growth (%)

6.56

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing contribution

North America at 45%

Key countries

US, Canada, Germany, UK, and France

Competitive landscape

Leading companies, Market Positioning of Vendors, Competitive Strategies and Industry Risks

Companies profiled

Alkermes Public Ltd. Co., Amneal Pharmaceuticals Inc., Aphios Corp., Braeburn Inc., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Indivior Plc, Johnson and Johnson, kaleo Inc., Mallinckrodt Plc, Orexo AB, Otsuka Holdings Co. Ltd., Pfizer Inc., Purdue Pharma LP, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Titan Pharmaceuticals Inc., and Viatris Inc.

Market Dynamics

Parent Market Analysis; Market growth inducers and obstacles; Fast-growing and slow-growing segment analysis for the forecast period

Customization preview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse Health Care Market Reports

Table of Contents

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis 
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027 
    • Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
    • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary
    • Exhibit 18: Five forces analysis – Comparison between 2022 and 2027
  • 4.2 Bargaining power of buyers 
    • Exhibit 19: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
  • 4.3 Bargaining power of suppliers 
    • Exhibit 20: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
  • 4.4 Threat of new entrants 
    • Exhibit 21: Threat of new entrants – Impact of key factors in 2022 and 2027
  • 4.5 Threat of substitutes 
    • Exhibit 22: Threat of substitutes – Impact of key factors in 2022 and 2027
  • 4.6 Threat of rivalry
    • Exhibit 23: Threat of rivalry – Impact of key factors in 2022 and 2027
  • 4.7 Market condition
    • Exhibit 24: Chart on Market condition – Five forces 2022 and 2027

5 Market Segmentation by Distribution Channel

  • 5.1 Market segments
    • Exhibit 25: Chart on Distribution Channel – Market share 2022-2027 (%)
    • Exhibit 26: Data Table on Distribution Channel – Market share 2022-2027 (%)
  • 5.2 Comparison by Distribution Channel 
    • Exhibit 27: Chart on Comparison by Distribution Channel
    • Exhibit 28: Data Table on Comparison by Distribution Channel
  • 5.3 Hospital pharmacy – Market size and forecast 2022-2027 
    • Exhibit 29: Chart on Hospital pharmacy – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 30: Data Table on Hospital pharmacy – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 31: Chart on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
    • Exhibit 32: Data Table on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
  • 5.4 Retail pharmacy – Market size and forecast 2022-2027 
    • Exhibit 33: Chart on Retail pharmacy – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 34: Data Table on Retail pharmacy – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 35: Chart on Retail pharmacy – Year-over-year growth 2022-2027 (%)
    • Exhibit 36: Data Table on Retail pharmacy – Year-over-year growth 2022-2027 (%)
  • 5.5 Others – Market size and forecast 2022-2027 
    • Exhibit 37: Chart on Others – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 38: Data Table on Others – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 39: Chart on Others – Year-over-year growth 2022-2027 (%)
    • Exhibit 40: Data Table on Others – Year-over-year growth 2022-2027 (%)
  • 5.6 Market opportunity by Distribution Channel 
    • Exhibit 41: Market opportunity by Distribution Channel ($ billion)

6 Market Segmentation by Type

  • 6.1 Market segments
    • Exhibit 42: Chart on Type – Market share 2022-2027 (%)
    • Exhibit 43: Data Table on Type – Market share 2022-2027 (%)
  • 6.2 Comparison by Type
    • Exhibit 44: Chart on Comparison by Type
    • Exhibit 45: Data Table on Comparison by Type
  • 6.3 Alcohol addiction therapeutics – Market size and forecast 2022-2027 
    • Exhibit 46: Chart on Alcohol addiction therapeutics – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 47: Data Table on Alcohol addiction therapeutics – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 48: Chart on Alcohol addiction therapeutics – Year-over-year growth 2022-2027 (%)
    • Exhibit 49: Data Table on Alcohol addiction therapeutics – Year-over-year growth 2022-2027 (%)
  • 6.4 Tobacco addiction therapeutics – Market size and forecast 2022-2027 
    • Exhibit 50: Chart on Tobacco addiction therapeutics – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 51: Data Table on Tobacco addiction therapeutics – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 52: Chart on Tobacco addiction therapeutics – Year-over-year growth 2022-2027 (%)
    • Exhibit 53: Data Table on Tobacco addiction therapeutics – Year-over-year growth 2022-2027 (%)
  • 6.5 Drug addiction therapeutics – Market size and forecast 2022-2027 
    • Exhibit 54: Chart on Drug addiction therapeutics – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 55: Data Table on Drug addiction therapeutics – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 56: Chart on Drug addiction therapeutics – Year-over-year growth 2022-2027 (%)
    • Exhibit 57: Data Table on Drug addiction therapeutics – Year-over-year growth 2022-2027 (%)
  • 6.6 Market opportunity by Type 
    • Exhibit 58: Market opportunity by Type ($ billion)

7 Customer Landscape

  • 7.1 Customer landscape overview 
    • Exhibit 59: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

8 Geographic Landscape

  • 8.1 Geographic segmentation 
    • Exhibit 60: Chart on Market share by geography 2022-2027 (%)
    • Exhibit 61: Data Table on Market share by geography 2022-2027 (%)
  • 8.2 Geographic comparison 
    • Exhibit 62: Chart on Geographic comparison
    • Exhibit 63: Data Table on Geographic comparison
  • 8.3 North America – Market size and forecast 2022-2027 
    • Exhibit 64: Chart on North America – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 65: Data Table on North America – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 66: Chart on North America – Year-over-year growth 2022-2027 (%)
    • Exhibit 67: Data Table on North America – Year-over-year growth 2022-2027 (%)
  • 8.4 Europe – Market size and forecast 2022-2027 
    • Exhibit 68: Chart on Europe – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 69: Data Table on Europe – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 70: Chart on Europe – Year-over-year growth 2022-2027 (%)
    • Exhibit 71: Data Table on Europe – Year-over-year growth 2022-2027 (%)
  • 8.5 Asia – Market size and forecast 2022-2027 
    • Exhibit 72: Chart on Asia – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 73: Data Table on Asia – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 74: Chart on Asia – Year-over-year growth 2022-2027 (%)
    • Exhibit 75: Data Table on Asia – Year-over-year growth 2022-2027 (%)
  • 8.6 Rest of World (ROW) – Market size and forecast 2022-2027 
    • Exhibit 76: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 77: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 78: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
    • Exhibit 79: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
  • 8.7 US – Market size and forecast 2022-2027 
    • Exhibit 80: Chart on US – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 81: Data Table on US – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 82: Chart on US – Year-over-year growth 2022-2027 (%)
    • Exhibit 83: Data Table on US – Year-over-year growth 2022-2027 (%)
  • 8.8 Germany – Market size and forecast 2022-2027 
    • Exhibit 84: Chart on Germany – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 85: Data Table on Germany – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 86: Chart on Germany – Year-over-year growth 2022-2027 (%)
    • Exhibit 87: Data Table on Germany – Year-over-year growth 2022-2027 (%)
  • 8.9 Canada – Market size and forecast 2022-2027 
    • Exhibit 88: Chart on Canada – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 89: Data Table on Canada – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 90: Chart on Canada – Year-over-year growth 2022-2027 (%)
    • Exhibit 91: Data Table on Canada – Year-over-year growth 2022-2027 (%)
  • 8.10 UK – Market size and forecast 2022-2027 
    • Exhibit 92: Chart on UK – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 93: Data Table on UK – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 94: Chart on UK – Year-over-year growth 2022-2027 (%)
    • Exhibit 95: Data Table on UK – Year-over-year growth 2022-2027 (%)
  • 8.11 France – Market size and forecast 2022-2027 
    • Exhibit 96: Chart on France – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 97: Data Table on France – Market size and forecast 2022-2027 ($ billion)
    • Exhibit 98: Chart on France – Year-over-year growth 2022-2027 (%)
    • Exhibit 99: Data Table on France – Year-over-year growth 2022-2027 (%)
  • 8.12 Market opportunity by geography 
    • Exhibit 100: Market opportunity by geography ($ billion)

9 Drivers, Challenges, and Trends

  • 9.1 Market drivers
  • 9.2 Market challenges
  • 9.3 Impact of drivers and challenges 
    • Exhibit 101: Impact of drivers and challenges in 2022 and 2027
  • 9.4 Market trends

10 Vendor Landscape

  • 10.1 Overview
  • 10.2 Vendor landscape
    • Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
  • 10.3 Landscape disruption
    • Exhibit 103: Overview on factors of disruption
  • 10.4 Industry risks
    • Exhibit 104: Impact of key risks on business

11 Vendor Analysis

  • 11.1 Vendors covered
    • Exhibit 105: Vendors covered
  • 11.2 Market positioning of vendors 
    • Exhibit 106: Matrix on vendor position and classification
  • 11.3 Alkermes Public Ltd. Co. 
    • Exhibit 107: Alkermes Public Ltd. Co. – Overview
    • Exhibit 108: Alkermes Public Ltd. Co. – Product / Service
    • Exhibit 109: Alkermes Public Ltd. Co. – Key news
    • Exhibit 110: Alkermes Public Ltd. Co. – Key offerings
  • 11.4 Amneal Pharmaceuticals Inc. 
    • Exhibit 111: Amneal Pharmaceuticals Inc. – Overview
    • Exhibit 112: Amneal Pharmaceuticals Inc. – Business segments
    • Exhibit 113: Amneal Pharmaceuticals Inc. – Key news
    • Exhibit 114: Amneal Pharmaceuticals Inc. – Key offerings
    • Exhibit 115: Amneal Pharmaceuticals Inc. – Segment focus
  • 11.5 Aphios Corp.
    • Exhibit 116: Aphios Corp. – Overview
    • Exhibit 117: Aphios Corp. – Product / Service
    • Exhibit 118: Aphios Corp. – Key offerings
  • 11.6 Braeburn Inc.
    • Exhibit 119: Braeburn Inc. – Overview
    • Exhibit 120: Braeburn Inc. – Product / Service
    • Exhibit 121: Braeburn Inc. – Key offerings
  • 11.7 Emergent BioSolutions Inc. 
    • Exhibit 122: Emergent BioSolutions Inc. – Overview
    • Exhibit 123: Emergent BioSolutions Inc. – Product / Service
    • Exhibit 124: Emergent BioSolutions Inc. – Key news
    • Exhibit 125: Emergent BioSolutions Inc. – Key offerings
  • 11.8 GlaxoSmithKline Plc
    • Exhibit 126: GlaxoSmithKline Plc – Overview
    • Exhibit 127: GlaxoSmithKline Plc – Business segments
    • Exhibit 128: GlaxoSmithKline Plc – Key offerings
    • Exhibit 129: GlaxoSmithKline Plc – Segment focus
  • 11.9 Glenmark Pharmaceuticals Ltd. 
    • Exhibit 130: Glenmark Pharmaceuticals Ltd. – Overview
    • Exhibit 131: Glenmark Pharmaceuticals Ltd. – Product / Service
    • Exhibit 132: Glenmark Pharmaceuticals Ltd. – Key offerings
  • 11.10 Hikma Pharmaceuticals Plc 
    • Exhibit 133: Hikma Pharmaceuticals Plc – Overview
    • Exhibit 134: Hikma Pharmaceuticals Plc – Business segments
    • Exhibit 135: Hikma Pharmaceuticals Plc – Key offerings
    • Exhibit 136: Hikma Pharmaceuticals Plc – Segment focus
  • 11.11 Indivior Plc
    • Exhibit 137: Indivior Plc – Overview
    • Exhibit 138: Indivior Plc – Product / Service
    • Exhibit 139: Indivior Plc – Key offerings
  • 11.12 Mallinckrodt Plc
    • Exhibit 140: Mallinckrodt Plc – Overview
    • Exhibit 141: Mallinckrodt Plc – Business segments
    • Exhibit 142: Mallinckrodt Plc – Key news
    • Exhibit 143: Mallinckrodt Plc – Key offerings
    • Exhibit 144: Mallinckrodt Plc – Segment focus
  • 11.13 Orexo AB
    • Exhibit 145: Orexo AB – Overview
    • Exhibit 146: Orexo AB – Product / Service
    • Exhibit 147: Orexo AB – Key offerings
  • 11.14 Otsuka Holdings Co. Ltd. 
    • Exhibit 148: Otsuka Holdings Co. Ltd. – Overview
    • Exhibit 149: Otsuka Holdings Co. Ltd. – Business segments
    • Exhibit 150: Otsuka Holdings Co. Ltd. – Key offerings
    • Exhibit 151: Otsuka Holdings Co. Ltd. – Segment focus
  • 11.15 Pfizer Inc.
    • Exhibit 152: Pfizer Inc. – Overview
    • Exhibit 153: Pfizer Inc. – Product / Service
    • Exhibit 154: Pfizer Inc. – Key news
    • Exhibit 155: Pfizer Inc. – Key offerings
  • 11.16 Teva Pharmaceutical Industries Ltd. 
    • Exhibit 156: Teva Pharmaceutical Industries Ltd. – Overview
    • Exhibit 157: Teva Pharmaceutical Industries Ltd. – Business segments
    • Exhibit 158: Teva Pharmaceutical Industries Ltd. – Key news
    • Exhibit 159: Teva Pharmaceutical Industries Ltd. – Key offerings
    • Exhibit 160: Teva Pharmaceutical Industries Ltd. – Segment focus
  • 11.17 Titan Pharmaceuticals Inc. 
    • Exhibit 161: Titan Pharmaceuticals Inc. – Overview
    • Exhibit 162: Titan Pharmaceuticals Inc. – Product / Service
    • Exhibit 163: Titan Pharmaceuticals Inc. – Key offerings

12 Appendix

  • 12.1 Scope of the report
  • 12.2 Inclusions and exclusions checklist 
    • Exhibit 164: Inclusions checklist
    • Exhibit 165: Exclusions checklist
  • 12.3 Currency conversion rates for US$ 
    • Exhibit 166: Currency conversion rates for US$
  • 12.4 Research methodology
    • Exhibit 167: Research methodology
    • Exhibit 168: Validation techniques employed for market sizing
    • Exhibit 169: Information sources
  • 12.5 List of abbreviations 
    • Exhibit 170: List of abbreviations
About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/addictions-therapeutics-market-2023-2027-5-year-2017-2021-historic-industry-size–analysis-of-15-vendors-and-7-countries-301685199.html

SOURCE Technavio

Addictions Therapeutics Market 2023-2027: 5-Year (2017-2021) Historic Industry Size & Analysis of 15 Vendors and 7 Countries WeeklyReviewer

PR Newswire Science News

World Reviewer Staff
World Reviewer Staffhttps://weeklyreviewer.com/
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

Related articles

WeeklyReviewer